Deals & Cases
Schellenberg Wittmer successfully represented Actavis in patent litigation against Eli Lilly
09.03.2017
Actavis, an affiliate of Teva Pharmaceutical Industries, one of the leading pharmaceutical companies worldwide, was successfully represented in a patent litigation by Schellenberg Wittmer’s IP Team (lead counsel Andrea Mondini) against Eli Lilly.
After having dismissed Eli Lilly's request for preliminary injunctions, the Swiss Federal Patent Court granted Actavis a declaratory judgment on the merits that Actavis' pemetrexed diacid product does not infringe Eli Lilly's patent EP 1 313 508 B1 claiming pemetrexed disodium for cancer treatment. This patent is heavily litigated in several countries, including Germany and the United Kingdom.
Teilen
Weitere Informationen
bundespatentgericht.chKontakt
Schellenberg Wittmer beriet ATP bei der Finanzierung derer Akquisition von Neschen Coating
08.10.2024
Schellenberg Wittmer hat ams-OSRAM beim Verkauf der "Passive Optical Components Assets" beraten
07.10.2024
Schellenberg Wittmer berät Meeberg Leasing Switzerland AG bei einer besicherten Finanzierungstransaktion über EUR 63 Millionen
26.09.2024